1 / 20

GCIG Rare Tumor Working Group Prague, CZ, October, 2010

GCIG Rare Tumor Working Group Prague, CZ, October, 2010. Chair: Isabelle Ray-Coquard Co-Chair: David M. Gershenson. Agenda:. Review of current clinical trials with update of status Review of clinical trials in development Establishment of listings of above to place on GCIG web site

step
Télécharger la présentation

GCIG Rare Tumor Working Group Prague, CZ, October, 2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GCIG Rare Tumor Working GroupPrague, CZ, October, 2010 Chair: Isabelle Ray-Coquard Co-Chair: David M. Gershenson

  2. Agenda: • Review of current clinical trials with update of status • Review of clinical trials in development • Establishment of listings of above to place on GCIG web site • Discussion of strategies and barriers to promote international collaboration • Potential future collaborations with IGCS • Roster of core members of Rare Tumor Working Group • approval for the Q&A issues with  providing commentary and feedback on submitted Q & As, and also agreement  to publish this as an audit of activity

  3. Active GOG Studies • GOG 187 (stromal tumors) • GOG 241 (MOC) • GOG 239 (low grade serous carcinoma) • GOG 251 (sex cords tumors) • GOG 245 (clear cell carcinoma) • GOG 0264 (sex cords tumors) • GOG 0268 (clear cell carcinoma)

  4. GOG 187: Phase II Study of Paclitaxel for Ovarian Stromal Tumors • Activated 11-2000 • Accrual: 27/37 pts. • Schema: Paclitaxel 175 mg/m2 IV Q. 21d as 2nd line therapy for pts. with measurable disease

  5. GOG 241: A GCIG Intergroup multicentre phase III trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous epithelial ovarian cancer (mEOC) Newly Diagnosed Stage II-IV or Recurrent Stage I Mucinous Ovarian Carcinoma Randomize 332 pts. Paclitaxel 175 mg/m2 Carboplatin AUC 6 Q. 21d X 6 Paclitaxel 175 mg/ m2 Carboplatin AUC 6 Bevacizumab 15 mg/kg Q. 21d X 6 Capecitabine 850 mg/m2 bd Oxaliplatin 130 mg/m2 Q. 21d X 6 Capecitabine 850 mg/m2 bd Oxaliplatin 130 mg/m2 Bevacizumab 15 mg/kg Q. 21d X 6 Bevacizumab 15 mg/kg Q. 21d X 12 Bevacizumab 15 mg/kg Q. 21d X 12 Activated 10-10 in US, 1500 pts attended

  6. GOG 239: Phase II Trial of AZD6244 in Women with Recurrent Low-Grade Serous Carcinoma of Ovary/Peritoneum • Activated 12-07 • Completed 1st stage accrual of 27 pts. in 9 mo. • Second stage opened on 5-26-09 • Accrual (52 pts.) completed in 11-09 • Awaiting analysis • Schema: AZD6244 for pts. with recurrent low-grade serous carcinoma with measurable disease

  7. GOG 251: Phase II Trial of Bevacizumab for Recurrent Sex Cord-Stromal Tumors of the Ovary • Activated 9-08 • Target accrual: Up to 37 pts. in 2-stage design • Completed 1st stage accrual • 2nd stage opened 9-10 • Accrual to date: 27 pts. • Schema: Bevacizumab 15 mg/kg IV Q. 21d for pts. with measurable disease

  8. GOG 254: Phase II evaluation of SU 11248 (sunitinib malate) in the treatment of persistent or recurrent clear cell ovarian carcinoma • Target accrual: 36-43 pts. in 2-stage design • Measurable disease • Activated in 4-10 • Accrual to date: 1 pt. • Schema: Sunitinib 50 mg QD

  9. GOG 0264: Phase II trial of paclitaxel and carboplatin vs. bleomycin, etoposide, and cisplatin for newly diagnosed advanced stage and recurrent chemonaive sex cord-stromal tumors of the ovary • Target accrual: 80-128 pts • Activated 2-10 • Accrual to date: 2 pts. • Schema: Phase II randomized study in 1:1 ratio

  10. GOG 0268: A phase II evaluation of temsirolimus (CCI-779) in combination with carboplatin and paclitaxel followed by temsirolimus (CCI-779) consolidation as first-line therapy in the treatment of stage III-IV clear cell carcinoma of the ovary • Schema: Temsirolimus (CCI-779) 25mg IV Days 1 and 8, Carboplatin AUC = 6 IV Day 1 and Paclitaxel 175 mg/m2 IV on Day 1 every 3 weeks for cycles 1-6 or disease progression. Followed by consolidation therapy with temsirolimus (CCI-779) 25 mg/kg weekly on Days 1, 8 and 15 every 3 weeks, cycles 7-22 or until disease progression • Target accrual: 45 pts. • Activated 8-10 • Accrual to date: 1 pt.

  11. Proposed GOG Studies

  12. RTM 0905: A phase II study of Dasatinib (Sprycel) in the treatment of vulvovaginal melanoma harboring somatic alterations of c-KIT • Study likely to be integrated into second stage of ongoing ECOG trial with separate cohort for women with vulvovaginal melanoma • Schema: Dasatinib 70 mg bid

  13. Other International Studies • ANZGOG: Phase 2 study of ARomatase inhibitors in women with potentially hormone responsive recurrent/metastatic Gynaecological Neoplasms (PARAGoN) • JGOG: Phase III randomized trial of irinotecan + cisplatin versus paclitaxel + carboplatin in treatment of newly diagnosed advanced stage clear cell carcinoma of the ovary

  14. UBC Study Proposal:Lapatanib or Traztusumab for Recurrent Ovarian Mucinous Carcinoma • Rationale: mucinous carcinomas overexpress HER-2/neu in 20% of cases • Extreme rarity of tumor type would likely require international participation • Surveying interest of GCIG cooperative groups

  15. Other proposals: • Philip Harter for uterine leiomyosarcoma • ?

  16. Agenda: • Review of current clinical trials with update of status • Review of clinical trials in development • Establishment of listings of above to place on GCIG web site • Discussion of strategies and barriers to promote international collaboration • Potential future collaborations with IGCS (M Bookman) • Roster of core members of Rare Tumor Working Group • approval for the Q&A issues with  providing commentary and feedback on submitted Q & As, and also agreement  to publish this as an audit of activity

  17. Agenda: • Review of current clinical trials with update of status • Review of clinical trials in development • Establishment of listings of above to place on GCIG web site • Discussion of strategies and barriers to promote international collaboration • Potential future collaborations with IGCS • Roster of core members of Rare Tumor Working Group • approval for the Q&A issues with  providing commentary and feedback on submitted Q & As, and also agreement  to publish this as an audit of activity

  18. Agenda: • Review of current clinical trials with update of status • Review of clinical trials in development • Establishment of listings of above to place on GCIG web site • Discussion of strategies and barriers to promote international collaboration • Potential future collaborations with IGCS • Roster of core members of Rare Tumor Working Group • approval for the Q&A issues with  providing commentary and feedback on submitted Q & As, and also agreement  to publish this as an audit of activity

  19. Agenda: • Review of current clinical trials with update of status • Review of clinical trials in development • Establishment of listings of above to place on GCIG web site • Discussion of strategies and barriers to promote international collaboration • Potential future collaborations with IGCS • Roster of core members of Rare Tumor Working Group • approval for the Q&A issues with  providing commentary and feedback on submitted Q & As, and also agreement  to publish this as an audit of activity

  20. Agenda: • Review of current clinical trials with update of status • Review of clinical trials in development • Establishment of listings of above to place on GCIG web site • Discussion of strategies and barriers to promote international collaboration • Potential future collaborations with IGCS • Roster of core members of Rare Tumor Working Group • Approval for the Q&A issues with  providing commentary and feedback on submitted Q & As, and also agreement  to publish this as an audit of activity

More Related